Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Jones Trading

Key Points

• Analysts at Jones Trading have reaffirmed a "hold" rating for Y-mAbs Therapeutics (NASDAQ:YMAB), while other firms have issued varying ratings, including an "outperform" with a lowered target price of $18.00 by Wedbush.
• The stock has suffered from recent downgrades, with Bank of America placing a "sell" rating and targeting a price of $3.00.
• Y-mAbs Therapeutics recently reported a quarterly earnings unexpected positive surprise with an EPS of ($0.12), surpassing the consensus estimate, alongside a revenue of $20.90 million.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) was downgraded by equities research analysts at Jones Trading from a "strong-buy" rating to a "hold" rating in a report issued on Tuesday, Marketbeat.com reports.

Several other brokerages have also recently commented on YMAB. Truist Financial decreased their target price on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Wedbush restated an "outperform" rating and set a $18.00 target price (down previously from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th. Oppenheimer decreased their target price on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. HC Wainwright decreased their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Finally, Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of "Hold" and an average price target of $11.16.

Y-mAbs Therapeutics Price Performance

Y-mAbs Therapeutics stock opened at $8.52 on Tuesday. The stock has a fifty day moving average price of $4.87 and a two-hundred day moving average price of $4.93. Y-mAbs Therapeutics has a 52-week low of $3.55 and a 52-week high of $16.11. The firm has a market capitalization of $385.79 million, a P/E ratio of -13.31 and a beta of 0.57.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 30.59% and a negative net margin of 31.84%. The firm had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. On average, equities research analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics in the fourth quarter valued at about $46,000. Brooklyn Investment Group boosted its holdings in Y-mAbs Therapeutics by 4,563.8% in the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock valued at $26,000 after acquiring an additional 5,796 shares during the last quarter. CWM LLC boosted its holdings in Y-mAbs Therapeutics by 203.0% in the second quarter. CWM LLC now owns 7,121 shares of the company's stock valued at $32,000 after acquiring an additional 4,771 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Y-mAbs Therapeutics in the second quarter valued at about $46,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Y-mAbs Therapeutics in the first quarter valued at about $49,000. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.